Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $8.03, but opened at $8.69. SELLAS Life Sciences Group shares last traded at $8.4920, with a volume of 1,994,249 shares traded.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners reaffirmed a "buy" rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, SELLAS Life Sciences Group presently has a consensus rating of "Hold" and a consensus price target of $10.00.
View Our Latest Stock Report on SLS
SELLAS Life Sciences Group Stock Up 3.0%
The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -39.33 and a beta of 2.73. The business's 50-day simple moving average is $11.15 and its two-hundred day simple moving average is $8.75.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05).
Institutional Trading of SELLAS Life Sciences Group
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP purchased a new stake in shares of SELLAS Life Sciences Group in the 3rd quarter valued at $632,000. Private Advisor Group LLC lifted its stake in SELLAS Life Sciences Group by 36.0% during the 3rd quarter. Private Advisor Group LLC now owns 21,278 shares of the company's stock worth $262,000 after acquiring an additional 5,628 shares in the last quarter. Voya Investment Management LLC lifted its stake in SELLAS Life Sciences Group by 358.1% during the 3rd quarter. Voya Investment Management LLC now owns 170,848 shares of the company's stock worth $2,103,000 after acquiring an additional 133,550 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in SELLAS Life Sciences Group by 15.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 27,688 shares of the company's stock valued at $341,000 after acquiring an additional 3,704 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in SELLAS Life Sciences Group by 42.2% during the 3rd quarter. Alps Advisors Inc. now owns 267,545 shares of the company's stock valued at $3,293,000 after acquiring an additional 79,438 shares during the period. Hedge funds and other institutional investors own 17.38% of the company's stock.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
